Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioNTech SE ( (BNTX) ) has provided an announcement.
On November 26, 2025, BioNTech SE announced the approval of its exchange offer for all outstanding shares of CureVac N.V., following an extraordinary general meeting held by CureVac on November 25, 2025. The offer, which expires on December 3, 2025, involves an exchange ratio of 0.05363 BioNTech ADS per CureVac share. The transaction aims to strengthen BioNTech’s market position by acquiring at least 80% of CureVac’s shares, with a potential reduction to 75% if conditions are met. This strategic move is expected to enhance BioNTech’s capabilities in the biopharmaceutical industry, benefiting stakeholders by expanding its portfolio and market reach.
The most recent analyst rating on (BNTX) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
Biopharmaceutical New Technologies (BioNTech) is a global next-generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. The company leverages computational discovery and therapeutic modalities to rapidly develop novel biopharmaceuticals. BioNTech’s diverse oncology product candidates include mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates and chimeric antigen receptor T cell therapies. Additionally, BioNTech is developing multiple mRNA vaccine candidates for infectious diseases and has partnerships with various global pharmaceutical companies.
Average Trading Volume: 941,471
Technical Sentiment Signal: Sell
Current Market Cap: $23.98B
See more data about BNTX stock on TipRanks’ Stock Analysis page.